APMAP

Across TCGA pan-cancer cohorts, APMAP mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated APMAP data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher APMAP mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated APMAP expression acts as an unfavorable survival marker.

CCRCC, HNSC, and PDAC are the cancer types where APMAP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.139	0.979	.001	33	view →
HNSC	DFS	Median	All	0.264	0.886	.002	29	view →
PDAC	DFS	Median	All	0.220	0.360	.030	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

APMAP–CCRCC (DFS)

Open the CCRCC breakdown →